Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Lbp Am Sa

LBP AM SA lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 43.3% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 230,201 shares of the medical research company's stock after buying an additional 69,507 shares during the period. Thermo Fisher Scientific comprises 1.8% of LBP AM SA's holdings, making the stock its 9th largest position. LBP AM SA owned 0.06% of Thermo Fisher Scientific worth $114,548,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in TMO. Axxcess Wealth Management LLC boosted its stake in Thermo Fisher Scientific by 8.3% in the 1st quarter. Axxcess Wealth Management LLC now owns 23,748 shares of the medical research company's stock worth $11,817,000 after purchasing an additional 1,823 shares during the period. Rehmann Capital Advisory Group lifted its position in Thermo Fisher Scientific by 1.7% during the 1st quarter. Rehmann Capital Advisory Group now owns 2,447 shares of the medical research company's stock worth $1,218,000 after buying an additional 42 shares in the last quarter. Cornerstone Planning Group LLC boosted its stake in shares of Thermo Fisher Scientific by 105.0% during the 1st quarter. Cornerstone Planning Group LLC now owns 123 shares of the medical research company's stock worth $61,000 after buying an additional 63 shares during the last quarter. Brick & Kyle Associates boosted its stake in shares of Thermo Fisher Scientific by 0.3% during the 1st quarter. Brick & Kyle Associates now owns 9,868 shares of the medical research company's stock worth $4,828,000 after buying an additional 30 shares during the last quarter. Finally, Linden Thomas Advisory Services LLC boosted its stake in shares of Thermo Fisher Scientific by 13.7% during the 1st quarter. Linden Thomas Advisory Services LLC now owns 5,397 shares of the medical research company's stock worth $2,686,000 after buying an additional 651 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on TMO. Argus reduced their price target on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. Royal Bank Of Canada decreased their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 target price on Thermo Fisher Scientific and gave the stock a "buy" rating in a report on Wednesday, April 23rd. UBS Group cut shares of Thermo Fisher Scientific from a "buy" rating to a "neutral" rating and cut their target price for the stock from $500.00 to $460.00 in a research note on Tuesday. Finally, Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus price target of $600.30.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded up $4.29 during trading on Friday, reaching $435.02. 2,511,384 shares of the company's stock were exchanged, compared to its average volume of 1,999,630. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88. The company has a market cap of $164.22 billion, a P/E ratio of 25.51, a PEG ratio of 2.31 and a beta of 0.77. The firm's 50-day moving average price is $409.39 and its 200 day moving average price is $476.23.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The company had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. During the same quarter in the previous year, the firm earned $5.11 EPS. Thermo Fisher Scientific's revenue was up .2% on a year-over-year basis. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.40%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's payout ratio is presently 10.09%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president directly owned 23,167 shares of the company's stock, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.